Biotricity Inc Reports Q4 2025 Earnings: Revenue Growth and Strategic Partnerships Drive Progress

Biotricity Inc (BTCY) reported a 16.5% YoY revenue increase to $3.7 million in Q4, driven by strategic partnerships and partnerships with Amazon AWS and Google's TensorFlow. The company secured alliances with three major group purchasing organizations, providing access to 90% of US hospitals, and achieved positive adjusted EBITDA of $438,000. However, Biotricity Inc reported a net loss of $11.9 million for FY25 and faces challenges in achieving profitability.

Biotricity Inc (BTCY) reported a robust 16.5% year-over-year (YoY) revenue increase to $3.7 million in the fourth quarter of 2025, driven by strategic partnerships and collaborations with major tech companies. The company’s Cardiac AI cloud platform, which utilizes Amazon AWS and Google’s TensorFlow, played a pivotal role in enhancing diagnostic accuracy and patient outcomes.

The company also secured strategic alliances with three major group purchasing organizations (GPOs), providing access to approximately 90% of U.S. hospitals. These partnerships have significantly expanded Biotricity’s market reach and customer base.

Biotricity achieved a positive adjusted EBITDA of $438,000 in the fourth quarter, marking progress towards profitability. The company's gross margin for the quarter stood at 80.4%, an improvement of over 890 basis points from the prior year. However, despite these positive developments, Biotricity reported a net loss of $11.9 million for the full fiscal year 2025, compared to $14.9 million in the prior year.

Operating expenses for the fiscal year 2025 were $13 million, a 24.5% decrease from the prior year. This reduction in operating expenses, coupled with the positive adjusted EBITDA, indicates that the company is making significant strides in cost control and operational efficiency.

Biotricity's CEO, Waqaas Al-Siddiq, expressed confidence in the company's ability to achieve greater acceleration in revenue from its GPO relationships, although he noted that the sales cycles for these partnerships are lengthy. The company anticipates that international market revenue contributions, such as from Saudi Arabia, may not significantly impact financials until 2026.

Looking ahead, Biotricity is focused on pursuing FDA clearance for its AI clinical model. The company plans to invest in monetizing its extensive data set, which could provide additional revenue streams. The Saudi Arabian market is expected to contribute to revenue growth in the coming years, with the company aiming for 20-30% of its business to be international in the near future.

Despite the challenges, Biotricity's strong Q4 financial results and operational efficiency improvements suggest that the company is approaching an inflection point on its path to profitability. The 14.3% YoY revenue growth to $13.8 million and the 8.9% margin expansion to 76.6% reflect the company’s successful implementation of AI-driven automation and optimization of its monitoring cost structure.

References:
[1] https://finance.yahoo.com/news/biotricity-inc-btcy-q4-2025-070629596.html
[2] https://www.stocktitan.net/news/BTCY/biotricity-delivers-strong-fiscal-year-2025-results-with-revenue-xbthcbkebngu.html